Tourette’s syndrome
Drug research and approvals for tourette’s syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 0 studies of tourette’s syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 0
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 0
Approved 3
- AripiprazoleDopamine D2 receptor partial agonist
- PimozideSerotonin 2a (5-HT2a) receptor antagonist
- HaloperidolSerotonin 2a (5-HT2a) receptor antagonist
Phase 3 7
- EcopipamDopamine D1 receptor antagonist
- TetrabenazineSynaptic vesicular amine transporter inhibitor
- TopiramateCarbonic anhydrase II inhibitor
- PramipexoleD2-like dopamine receptor agonist
- GuanfacineAdrenergic receptor alpha-2 agonist
- TiaprideDopamine D3 receptor antagonist
- Nabiximols
Phase 2 12
- ValbenazineSynaptic vesicular amine transporter inhibitor
- DronabinolCannabinoid CB1 receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- ElcubragistatMonoglyceride lipase inhibitor
- Cannabinol
- AtomoxetineNorepinephrine transporter inhibitor
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- PF-03654746Histamine H3 receptor antagonist
- AcetylcysteineGlutathione precursor
- Palmidrol
- Sepranolone
- Gemlapodect
Phase 1 or earlier 6
- VigabatrinGamma-amino-N-butyrate transaminase inhibitor
- LevodopaDopamine D3 receptor agonist
- VatiquinoneQuinone reductase 1 modulator
- RedafamdastatAnandamide amidohydrolase inhibitor
- PimavanserinSerotonin 2a (5-HT2a) receptor inverse agonist
- CycloserineD-alanylalanine synthetase inhibitor
How its trials ended
216 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 54 whose ending is known, 43% met their primary endpoint, 11% missed it and 46% stopped early.
- Completed, result not reported10247%
- Ongoing3717%
- Met its primary endpoint2311%
- Status unknown2311%
- Stopped: other or unclear157%
- Missed its primary endpoint63%
- Stopped: enrollment or feasibility63%
- Stopped: lack of efficacy31%
- Stopped: funding1<1%
| May 31, 2019 | A multicenter, open-label, extension study intended to evaluate the long-term safety of ecopipam tablets in children and adolescent subjects with tourette's…Ecopipam (EBS-101) | Emalex Biosciences, Inc | Closed |
| May 31, 2019 | A multicenter, placebo-controlled, double-blind, randomized, parallel-group, phase 2b study to evaluate the efficacy and safety of ecopipam tablets in children…Ecopipam | Emalex Biosciences, Inc | Closed |
| Jan 17, 2019 | A well-controlled, fixed-dose study of TEV-50717 (deutetrabenazine) for the treatment of tics associated with tourette syndromeDeutetrabenazine (TEV-50717) | Teva Pharmaceutical Industries | Pending |
| Apr 10, 2018 | An open-label, long-term safety study including a double-blind, placebo-controlled, randomized withdrawal period of TEV-50717 (deutetrabenazine) for the…Deutetrabenazine (TEV-50717) | Teva Pharmaceutical Industries | Ongoing |
| Dec 21, 2017 | A randomized, double-blind, placebo-controlled study of TEV-50717 (deutetrabenazine) for the treatment of tourette syndrome in children and adolescentsDeutetrabenazine (TEV-50717) | Teva Pharmaceutical Industries | Closed |
| Dec 10, 2014 | A double-blind, randomized, placebo-controlled crossover pilot trial of medical cannabis in adults with tourette syndrome.Delta-9-tetrahydrocannabinol-cannabidiol | Dr Paul Sandor | Ongoing |
| Dec 12, 2014 | AbilifyTreatment of pediatric patients with Tourette's | Otsuka Pharmaceutical Development | Approved |
| Mar 30, 2017 | (+)-a-dihydrotetrabenazineTreatment pediatric patients with Tourette's syndrome | Adeptio Pharmaceuticals, Ltd | Designated |
| Mar 17, 2016 | Guanfacine and amphetamineTreatment of pediatric patients with Tourette's syndrome (0 through 16 years of age) | KemPharm, Inc. | Designated |
| Sep 29, 2010 | Ecopipam hydrochlorideTreatment of pediatric patients with Tourette's syndrome. | Emalex Biosciences, Inc. | Designated |
| Jul 1, 2009 | TetrabenazineTreatment of Tourette's Syndrome in school-age children, ages 5-16 | Valeant International (Barbados) SRL | Designated |
| Jan 31, 2008 | PramipexoleTreatment of Tourette's syndrome in pediatric patients | Boehringer-Ingelheim Pharmaceuticals, Inc. | Designated |
| Aug 26, 2003 | Atomoxetine hydrochlorideTreatment of Tourette's Syndrome | Eli Lilly & Company | Designated |
| Oct 14, 1998 | MecamylamineTreatment of Tourette's syndrome. | Targacept, Inc. | Designated |
| Apr 21, 1998 | TiaprideTreatment of Tourette's syndrome. | Sanofi-Synthelabo, Inc. | Designated |
| Nov 20, 1997 | PergolideTreatment of Tourette's syndrome. | Sallee, Floyd R. M.D., Ph.D. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA